JANUARY 13, 2020

Canadian GI Groups Take Stand Against Nonmedical Biosimilar Switching

The Canadian Association of Gastroenterology and Crohn’s and Colitis Canada have issued a joint statement on biosimilars in the treatment of inflammatory bowel disease, recommending against automatic substitution of the drugs for their reference products and urging that patients who are stable on biologic treatment should not be subject to nonmedical switching.

The move that places them somewhat at odds with European organizations that also oppose automatic switching but have issued public